Prof. Dirk Busch


Prof. Dirk Busch

Technische Universität München, Germany

Details of the visit to be announced

Hosted by Steven Turner, University of Melbourne, VIC


After studying medicine in Mainz and Freiburg (1993) and completing his doctorate (1993), Prof. Busch commenced his clinical training in infectious pediatrics (Würzburg, 1993-1996). A German Research Foundation scholarship gave him the opportunity to study under Prof. Eric Pamer at Yale University (1996-1999). He qualified as a lecturer in 2003 and completed his residency in medical microbiology and epidemiology of infection (2005) at TUM. Prof. Busch heads up the “Antigen-Specific Immunotherapy” clinical cooperation group (Helmholtz Zentrum München and TUM) and the IAS focus group “Clinical Cell Processing and Purification”. He has held the position of director of TUM’s Institute for Medical Microbiology, Immunology and Hygiene since 2009.


Professor Busch’s research is focused on antigen-specific T cells and the development of new technologies to make immune cells usable for diagnostic and cell therapy applications. He has published over 180 peer reviewed papers making several seminal contributions to the field which include: understanding T cell fate decisions upon activation, understanding how heterogeneity of T cell effector function is regulated and contributes to immune protection and more recently how T cells can be utilized for immunotherapy. Prof. Busch conducts research into infection immunology with the goal of identifying therapeutically useful defense mechanisms. His work centers on antigen-specific T cells and the development of new technologies to make immune cells usable for diagnostic and cell therapy applications.


Selected publications in the last 5 years

Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Höfer T, Riddell SR, Busch DH. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. Jul 17;41(1):116-26, 2014.

Stemberger et al., Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood, pii: blood-2013-12-547349, 2014.

Nuemann et al., Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity. 40:389, 2014.

Weissbrich et al. Adoptive immunotherapy: New assay for the identification of T cells with optimal avidity. Oncoimmunology. 2:e26199, 2013.

Nauerth et al., TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med. 5:192ra87, 2013.

Buchholz et al., Disparate individual fates compose robust CD8+ T cell immunity. Science. 340:630-5, 2013.

Neuenhahn and Busch. Whole body analtomy of human T cells. Immunity. 38(1):10, 2013.

Buchholz et al., The origin of diversity: studying the evolution of multi-faceted CD8+ T cell responses. Cell Mol Life Sci. 69:1585-95., 2012.

Verschoor et al., A platelet-mediated system for shuttling blood-borne bacteria to CD8?+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol. 12:1194, 2011.

Buchholz et al., CD8+ T cell differentiation in the aging immune system: until the last clone standing. Curr Opin Immunol. 23:549, 2011.

Neuenhahn and Busch. The quest for CD8+ memory stem cells. Immunity, 31: 702, 2009.